Abstract
Hepatitis C is a virus affecting millions worldwide and is a major health risk. With the potentially severe adverse event profile of the current backbone of therapy, interferon, there is an impetus to discover interferon free treatment regimens. With the development of new oral direct acting antivirals, interferon free regimens may be available in the next few years. This article discusses some of the preliminary data from interferon free studies.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Drug Therapy, Combination
-
Hepatitis C / drug therapy*
-
Humans
-
Interferon-alpha / adverse effects
-
Interferon-alpha / therapeutic use*
-
Protease Inhibitors / therapeutic use*
-
Ribavirin / adverse effects
-
Ribavirin / therapeutic use*
-
Sofosbuvir
-
Uridine Monophosphate / analogs & derivatives*
-
Uridine Monophosphate / therapeutic use
Substances
-
Antiviral Agents
-
Interferon-alpha
-
Protease Inhibitors
-
Ribavirin
-
Uridine Monophosphate
-
Sofosbuvir